BioCryst Pharmaceuticals Ownership | Who Owns BioCryst Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

BioCryst Pharmaceuticals Ownership Summary


BioCryst Pharmaceuticals is owned by 108.82% institutional investors, 1.20% insiders. Vanguard group is the largest institutional shareholder, holding 10.60% of BCRX shares. BioPharma Credit Ord is the top mutual fund, with 8.23% of its assets in BioCryst Pharmaceuticals shares.

BCRX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockBioCryst Pharmaceuticals108.82%1.20%-10.02%
SectorHealthcare Stocks 244.59%12.11%-156.70%
IndustryBiotech Stocks 379.61%11.70%-291.31%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group22.27M10.60%$173.73M
Blackrock funding, inc. /de23.89M9.86%$238.93M
Blackrock19.96M9.68%$123.33M
Ra capital management15.83M6.53%$158.27M
State street15.19M6.27%$151.91M
Deerfield management company, l.p. (series c)15.10M6.23%$150.96M
Vanguard capital management11.36M4.69%$113.64M
Tcg crossover management11.02M4.55%$110.21M
Perceptive advisors10.31M4.26%$103.09M
Janus henderson group8.91M4.22%$84.85M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Rp management3.85M12.84%$29.23M
Rosalind advisors721.50K2.68%$7.22M
Tcg crossover management11.02M2.65%$110.21M
Vestal point capital, lp8.30M1.94%$83.00M
Cannon global investment management59.70K1.69%$597.00K
Parkman healthcare partners1.62M1.66%$16.24M
Deerfield management company, l.p. (series c)15.10M1.57%$150.96M
Perceptive advisors10.31M1.55%$103.09M
Kynam capital management, lp2.52M1.39%$25.23M
Ra capital management15.83M1.38%$158.27M

Top Buyers

HolderShares% AssetsChange
Millennium management3.39M0.01%3.21M
State street15.19M0.00%2.98M
Perceptive advisors10.31M1.55%2.87M
Hood river capital management3.62M0.32%2.38M
Sixth street partners management company2.35M0.00%2.35M

Top Sellers

HolderShares% AssetsChange
Braidwell lp---3.38M
Avoro capital advisors1.25M0.12%-3.25M
Kynam capital management, lp2.52M1.39%-3.16M
Rfg advisory---2.87M
Baker bros. advisors lp---2.82M

New Positions

HolderShares% AssetsChangeValue
Sixth street partners management company2.35M0.00%2.35M$23.53M
Cubist systematic strategies1.25M0.05%1.25M$9.46M
Moore capital management, lp848.34K0.13%848.34K$8.48M
Norges bank524.80K0.00%524.80K$3.95M
Nan fung trinity (hk)450.00K0.44%450.00K$4.50M

Sold Out

HolderChange
Tfo-tdc-3.00
Aster capital management (difc)-6.00
Financial gravity asset management-8.00
Dinuzzo private wealth-13.00
Newbridge financial services group-15.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20263315.08%263,633,5825.85%1081.03%189-1.05%8714.47%
Mar 31, 2026211-27.49%108,497,915-48.95%510.50%123-13.99%48-52.00%
Dec 31, 202579-73.04%34,367,278-82.30%160.19%37-72.79%25-75.49%
Sep 30, 2025101-65.88%38,849,402-78.37%180.25%42-73.58%35-57.83%
Jun 30, 20253049.35%196,946,75415.72%941.42%1615.92%8630.30%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
BioPharma Credit Ord17.22M8.23%17.22M
State Street® SPDR® S&P® Biotech ETF9.41M3.68%21.60K
Vanguard Total Stock Mkt Idx Inv8.07M3.18%11.39K
Vanguard Morn Total Stk Mkt Idx Investor8.07M3.18%11.39K
Vanguard MStar Total Stk Mkt Idx Invest8.11M3.17%37.13K
Vanguard US Total Market Shares ETF6.57M3.14%-18.55K
iShares Russell 2000 ETF5.92M2.32%-105.12K
SPDR® S&P Biotech ETF3.67M1.75%8.19K
Vanguard Small Cap Index2.93M1.15%6.29K
Vanguard Institutional Extnd Mkt Idx Tr2.84M1.11%4.92K

Recent Insider Transactions


DateNameRoleActivityValue
May 18, 2026McKee Amy E-Sell$100.28K
May 13, 2026Barnes Alane P Chief Legal OfficerSell$596.25K
Mar 20, 2026HEGGIE THERESA-Sell$504.82K
Mar 16, 2026Barnes Alane P Chief Legal OfficerSell$1.37M
Dec 22, 2025Barnes Alane P Chief Legal OfficerSell$166.56K

Insider Transactions Trends


DateBuySell
2026 Q4--
2026 Q1--
2025 Q4-6
2025 Q3-1
2025 Q2--

BCRX Ownership FAQ


Who Owns BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals shareholders are primarily institutional investors at 108.82%, followed by 1.20% insiders and -10.02% retail investors. The average institutional ownership in BioCryst Pharmaceuticals's industry, Biotech Stocks , is 379.61%, which BioCryst Pharmaceuticals falls below.

Who owns the most shares of BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals’s largest shareholders are Vanguard group (22.27M shares, 10.60%), Blackrock funding, inc. /de (23.89M shares, 9.86%), and Blackrock (19.96M shares, 9.68%). Together, they hold 30.14% of BioCryst Pharmaceuticals’s total shares outstanding.

Does Blackrock own BioCryst Pharmaceuticals?

Yes, BlackRock owns 9.68% of BioCryst Pharmaceuticals, totaling 19.96M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 123.33M$. In the last quarter, BlackRock increased its holdings by 1.52M shares, a 8.22% change.

Who is BioCryst Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Rp management is BioCryst Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 12.84% of its assets in 3.85M BioCryst Pharmaceuticals shares, valued at 29.23M$.

Who is the top mutual fund holder of BioCryst Pharmaceuticals shares?

BioPharma Credit Ord is the top mutual fund holder of BioCryst Pharmaceuticals shares, with 8.23% of its total shares outstanding invested in 17.22M BioCryst Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools